Goldline Pharmaceutical Ltd
Goldline Pharmaceutical Ltd (GLPL) last traded at ₹40, a market capitalisation of ₹38.4 crore, on a P/E of 9.32. Over the past 52 weeks the stock has ranged between ₹33 and ₹60. Goldline Pharmaceutical Ltd last reported results for the quarter ended Mar 2026, with sales of ₹17.31 crore and net profit of ₹2.76 crore. Goldline Pharmaceutical Ltd’s annual general meeting is scheduled for 29 Aug 2026. Figures are as of 25 Aug 2026 and are not real time.
Goldline Pharmaceutical Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Goldline Pharmaceutical Ltd quarterly results
| ₹ crore | Sep 2025 | Mar 2026 |
|---|---|---|
| Sales | 13.89 | 17.31 |
| Expenses | 11.25 | 13 |
| Operating profit | 2.64 | 4.31 |
| OPM % | 19.01% | 24.90% |
| Other income | 0 | 0 |
| Interest | 0.67 | 0.65 |
| Depreciation | 0.12 | 0.12 |
| Profit before tax | 1.85 | 3.54 |
| Tax % | 26.49% | 21.75% |
| Net profit | 1.36 | 2.76 |
| EPS (₹) | 1.97 | 4.00 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Goldline Pharmaceutical Ltd annual results
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 19.73 | 23.48 | 28.01 | 31.18 |
| Operating profit | 2.41 | 4.34 | 6.15 | 7.09 |
| OPM % | 12.21% | 18.48% | 21.96% | 22.74% |
| Net profit | 0.26 | 1.81 | 2.83 | 4.12 |
| EPS (₹) | 1.30 | 7.87 | 4.10 | 5.97 |
TTM is the trailing twelve months to the most recent quarter.
Goldline Pharmaceutical Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 16%
- TTM
- 11%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 119%
- TTM
- 42%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- %
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 39%
- Last Year
- 39%
Goldline Pharmaceutical Ltd shareholding pattern
| % held | May 2026 |
|---|---|
| Promoters | 57.29% |
| FIIs | 5.16% |
| DIIs | 7.81% |
| Public | 29.74% |
| No. of shareholders | 271 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Goldline Pharmaceutical Ltd’s AGM?
Goldline Pharmaceutical Ltd’s annual general meeting is scheduled for 29 Aug 2026.
- AGM22nd Annual General Meeting including adoption of financial statements, dividend on preference shares, director re-appointment, and approval of material related party transactions and loan borrowing limits.
See the full results calendar for every Indian company reporting in the next 30 days.
Goldline Pharmaceutical Ltd corporate filings
- Notice published by way of an advertisement in respect of 22nd Annual General Meeting (AGM) of the Company.Company Updatelow impact
Cruxal's analysis: Goldline Pharmaceutical Limited has issued a formal notice regarding its 22nd Annual…
Read the full analysis - Intimation of Record Date for remote e-votingCorp. Actionlow impact
Cruxal's analysis: Goldline Pharmaceutical Ltd has issued an intimation regarding the record date for remote…
Read the full analysis - Intimation of Book ClosureCorp. Actionlow impact
Cruxal's analysis: Goldline Pharmaceutical Ltd has announced the closure of its register of members from…
Read the full analysis - Submission of Annual Report of Goldline Pharmaceutical Limited for FY 2025-26.Otherslow impact
Cruxal's analysis: Goldline Pharmaceutical Ltd has filed its Annual Report for the financial year 2025-26 as…
Read the full analysis - Intimation of notice of 22nd AGM of Goldline Pharmaceutical Limited.AGM/EGMmedium impact
Cruxal's analysis: Goldline Pharmaceutical Limited has scheduled its 22nd Annual General Meeting for August…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Goldline Pharmaceutical Ltd
Cruxal reads every Goldline Pharmaceutical Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.